These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 17951334

  • 1. Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
    Lee SS, Kim SB, Park SI, Kim YH, Ryu JS, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH.
    Jpn J Clin Oncol; 2007 Nov; 37(11):829-35. PubMed ID: 17951334
    [Abstract] [Full Text] [Related]

  • 2. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK.
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB.
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM.
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [Abstract] [Full Text] [Related]

  • 5. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):427-36. PubMed ID: 15380576
    [Abstract] [Full Text] [Related]

  • 6. Nonsurgical management of esophageal adenocarcinoma.
    Gujral DM, Hawkins MA, Leonulli BG, Ashley S, Chau I, Cunningham D, Tait D.
    Clin Colorectal Cancer; 2011 Sep 01; 10(3):165-70. PubMed ID: 21855037
    [Abstract] [Full Text] [Related]

  • 7. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA, Hainsworth JD.
    J Clin Oncol; 2010 May 01; 28(13):2213-9. PubMed ID: 20351330
    [Abstract] [Full Text] [Related]

  • 8. [Capecitabine combined with cisplatin as first-line therapy in Chinese patients with advanced gastric carcinoma-a phase II clinical study].
    Hu B, Yu JR, Wen ZZ, Shu YQ, Wang BC, Yin HR, Chen L, Bai YX, Liang J, Chen L, Cheng Y, Shen L, Zhou Y, Zhang HG, Li J, Wan DS, Chen S, Jia TZ, Jin ML.
    Zhonghua Zhong Liu Za Zhi; 2008 Dec 01; 30(12):940-3. PubMed ID: 19173999
    [Abstract] [Full Text] [Related]

  • 9. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A, Felekouras E, Karatzas T, Griniatsos J, Dimitroulis D, Polyzos K, Kontzoglou K, Mantas D, Karavokyros J, Nikiteas N, Tsavaris N, Syrigos K, Vafiadis I.
    Anticancer Res; 2012 Sep 01; 32(9):4151-6. PubMed ID: 22993377
    [Abstract] [Full Text] [Related]

  • 10. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD.
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):691-7. PubMed ID: 20888705
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma.
    Li YH, Wang FH, Jiang WQ, Xiang XJ, Deng YM, Hu GQ, Xu DM, Chen Y, Lin Q, He YJ.
    Cancer Chemother Pharmacol; 2008 Aug 01; 62(3):539-44. PubMed ID: 18172651
    [Abstract] [Full Text] [Related]

  • 12. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM, Lee JM, Huang PM, Lin CC, Hsu CH, Tsai YC, Lee YC, Chia-Hsien Cheng J.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e593-9. PubMed ID: 21658851
    [Abstract] [Full Text] [Related]

  • 13. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM, Lee WJ, Han SS, Park SJ, Kim TH, Koh YH, Kim HB, Hong EK, Park JW, Kim CM.
    Chemotherapy; 2012 Nov 15; 58(3):225-32. PubMed ID: 22831988
    [Abstract] [Full Text] [Related]

  • 14. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N, Park SD, Lynch T, Wright C, Ancukiewicz M, Wain J, Donahue D, Mathisen D.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):111-22. PubMed ID: 15337546
    [Abstract] [Full Text] [Related]

  • 15. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
    Zhang XD, Shen L, Li J, Li Y, Li J, Zhang XT, Jin ML.
    Zhonghua Zhong Liu Za Zhi; 2007 Jun 01; 29(6):474-7. PubMed ID: 17974288
    [Abstract] [Full Text] [Related]

  • 16. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.
    Cancer Chemother Pharmacol; 2007 Aug 01; 60(3):321-8. PubMed ID: 17143602
    [Abstract] [Full Text] [Related]

  • 17. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
    Kelsey CR, Chino JP, Willett CG, Clough RW, Hurwitz HI, Morse MA, Bendell JC, D'Amico TA, Czito BG.
    Int J Radiat Oncol Biol Phys; 2007 Nov 01; 69(3):770-6. PubMed ID: 17889266
    [Abstract] [Full Text] [Related]

  • 18. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z, Zhang Z, Jin J, Ajani JA, Swisher SG, Stevens CW, Ho L, Smythe R, Vaporciyan AA, Putnam JB, Walsh GL, Roth JA, Yao JC, Allen PK, Cox JD, Komaki R.
    Int J Radiat Oncol Biol Phys; 2004 Dec 01; 60(5):1484-93. PubMed ID: 15590179
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS, Khorana AA, Javle M, Simon S, Kiefer G, Rajasenan K, Wang H, Hantel A, Shayne M, Hwang J, Schmotzer A, Ramanathan RK.
    Oncology; 2010 Dec 01; 78(2):125-9. PubMed ID: 20389134
    [Abstract] [Full Text] [Related]

  • 20. Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study.
    Evans D, Miner T, Iannitti D, Akerman P, Cruff D, Maia-Acuna C, Harrington D, Habr F, Chauhan B, Berkenblit A, Stuart K, Sears D, Kennedy T, Safran H.
    Cancer Invest; 2007 Sep 01; 25(6):445-8. PubMed ID: 17882656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.